A recent study posted to the medRxiv* preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system (RAAS) inhibitors conferred reduced risks for starting dialysis or needing ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

Investigators found no definitive benefit of dual RAAS blockade in preventing kidney failure in patients with ADPKD. For patients with autosomal dominant polycystic kidney disease (ADPKD), intensive ...

In this rapidly evolving setting, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their ...